BRIEF—Helsinn Therapeutics appoints new chief executive

Switzerland’s Helsinn Group has appointed Paul Rittman as chief executive of its US subsidiary Helsinn Therapeutics, replacing William Mann, who steps down on February 28, 2018.

Mr Rittman was most recently senior VP and general manager of oncology at Teva Pharmaceutical Industries’ US business.

Helsinn also recently expanded its footprint in China by opening an office in Shanghai.